Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.

Julian Hirt Kinga Dembowska Tim Woelfle Cathrine Axfors Cristina Granziera Jens Kuhle Ludwig Kappos Lars G Hemkens Perrine Janiaud

Published in: Journal of neurology (2024)

Certain DMTs have the potential to positively impact QoL of PwMS, and the assessment and reporting of QoL is suboptimal with a multitude of diverse instruments being used. There is an urgent need that design and reporting of clinical trials reflect the critical importance of QoL for PwMS.

Keyphrases

clinical trial
multiple sclerosis
adverse drug
phase ii
open label
double blind
phase iii
study protocol
emergency department
white matter
risk assessment
human health
data analysis